Ozanimod - Celgene Corporation
Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIALatest Information Update: 18 Dec 2023
At a glance
- Originator The Scripps Research Institute
- Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
- Class Amines; Anti-inflammatories; Antivirals; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis; Ulcerative colitis
- Phase III Crohn's disease
- Phase II COVID 2019 infections
Most Recent Events
- 21 Nov 2023 Celgene completes a phase III trial in Crohn's disease in USA, Turkey, Taiwan, Sweden, South Korea, South Africa, Slovenia, Slovakia, Singapore, Serbia, Saudi Arabia, Russia, Portugal, Netherlands, Mexico, Lithuania, Israel, Hong Kong, Greece, Germany, Canada, Ukraine, Australia, Austria, Brazil, China, Finland, France, Georgia, Colombia and Senegal (PO) (NCT03440385)
- 15 Nov 2023 Celgene completes a phase IIIb trial for Multiple sclerosis in the US and Germany (PO) (NCT05028634)
- 14 Oct 2023 Efficacy and adverse event data from a phase I trial in Ulcerative colitis presented at the 31st United European Gastroenterology Week (UEG-2023)